Neil Dunavin, MD, MS, discusses frontline treatment in myelofibrosis.
Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment in myelofibrosis.
Myelofibrosis is a highly symptomatic disease, explains Dunavin. Patients with myelofibrosis may have low blood counts that require transfusion, fatigue, sweats, and enlarged spleens.
Ruxolitinib (Jakafi) is the current frontline standard of care for patients with myelofibrosis who have adequate blood counts, says Dunavin. In November 2011, the oral JAK1/2 inhibitor became the first drug to receive regulatory approval for the treatment of patients with myelofibrosis.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
2 Commerce Drive
Cranbury, NJ 08512